MiR-183-5p promotes renal cell carcinoma metastasis by targeting TET1
International Journal of Immunopathology and Pharmacology · 2023
DOI: 10.1177/03946320231184997 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Immunopathology and Pharmacology, 2023. Verfasst von Shengnan Jin und 7 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Drug Metabolism and Pharmaceutical Analysis, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sc…. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, MicroRNAs, Kidney Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Natural Science Foundation of Zhejiang Province, National Natural Science Foundation of China.
Abstract (Originalsprache)
Ten-eleven translocation 1 (TET1) is a member of the DNA demethylase family that regulates the methylation level of the genome. Dysregulation of TET1 in renal cell carcinoma (RCC) may be associated with RCC progression, but the mechanism of TET1 down-regulation in RCC is not yet known. MiR-183-5p is up-regulated in various tumor tissues and acts as an oncogene. We used Transwell and wound healing assays to test cell invasion and migration. To investigate DNA methylation, we used dot blot, which indicates TET1 enzyme activity. We verified the binding of miR-183-5p and TET1 3′-UTR (untranslated region) using dual-luciferase reporter assay. Our study demonstrated, for the first time, that miR-183-5p can directly repress TET1 expression in RCC. We observed a significant decrease in TET1 expression in RCC specimens, as reported in the literature, and a significant decrease in the concentration of 5hmC in RCC. By aligning the microRNA with a database and using the luciferase reporter gene method, we found that miR-183-5p can inhibit luciferase activity by binding to 453-459 bp of TET1 3′-UTR, leading to inhibition of TET1 expression. Furthermore, down-regulation of TET1 inhibited miR-200c expression and promoted RCC cell invasion and migration. Our findings suggest that in RCC, increased expression of miR-183-5p inhibits the expression of TET1, which in turn inhibits the expression of miR-200c and E-cadherin, both of which are associated with cell adhesion. This leads to the promotion of cell invasion and migration.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Drug Metabolism and Pharmaceutical Analysis, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China.
- National Key Laboratory of Advanced Drug Delivery and Release Systems, Zhejiang University, Hangzhou, China.
- Center for Clinical Pharmacy, Cancer Center, Department of Pharmacy, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, China.
- Department of Urology, Cancer Hospital of Zhejiang Province, Hangzhou, China.
ORCID-Profile: Shengnan Jin
Förderung
- Natural Science Foundation of Zhejiang Province
- National Natural Science Foundation of China
Zitieren
APA
Jin, S., Chen, L., Wu, J., Chen, M., Wang, H., Hu, H., Yu, L., & Zeng, S. (2023). MiR-183-5p promotes renal cell carcinoma metastasis by targeting TET1. International Journal of Immunopathology and Pharmacology. https://doi.org/10.1177/03946320231184997
Vancouver
Jin S, Chen L, Wu J, Chen M, Wang H, Hu H, et al. MiR-183-5p promotes renal cell carcinoma metastasis by targeting TET1. International Journal of Immunopathology and Pharmacology. 2023. doi:10.1177/03946320231184997
BibTeX
@article{Jin2023,
author = {Jin, Shengnan and Chen, Lu and Wu, Jiayi and Chen, Mengjiao and Wang, Hua and Hu, Haihong and Yu, Lushan and Zeng, Su},
title = {MiR-183-5p promotes renal cell carcinoma metastasis by targeting TET1},
journal = {International Journal of Immunopathology and Pharmacology},
year = {2023},
doi = {10.1177/03946320231184997}
}
EUVIMED